Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Research-Driven Firms Should Not Rely on Off-Patent Products: Mr Kinoshita
July 13, 2009
- TOPICS 2 articles
July 13, 2009
- Korosho to Create Prevention-Oriented Medical Safety System: Mr Mori
July 13, 2009
- Quintiles Leads Int'l Clinical Trials in Asia
July 13, 2009
- REGULATORY NEWS IN BRIEF
July 13, 2009
- Eisai Gives Up Filing Application for Pediatric Indication for Aricept
July 13, 2009
- Astellas to Fill Shortfall in Late-Stage Development with Licensing
July 13, 2009
- Eisai Launches New R&D Organization
July 13, 2009
- GSK Drops SGLT2 Inhibitor Licensed from Kissei
July 13, 2009
- Chugai Obtains 51% Share in Market for Antibody Pharmaceuticals in Japan
July 13, 2009
- Wyeth Enters into Comprehensive Agreement with NHO for Clinical Trials
July 13, 2009
- Nippon Kayaku: Generics Drive Sales Up to ¥45.77 Bil.
July 13, 2009
- i3 to Embark on CRO Market in Japan in Earnest
July 13, 2009
- ON THE MOVE
July 13, 2009
- Selection of Patients Holds Key to Success of Molecular-Targeted Drugs
July 13, 2009
- BUSINESS NEWS IN BRIEF
July 13, 2009
- 2009 IP Promotion Plan Calls For Patent Protection for New Dosage and Treatment Regimens
July 13, 2009
- Nissui Pharma. to Market Switch OTC Version of Epadel from Mochida
July 13, 2009
- JSGM Presents Proposals to Promote Use of Generics
July 13, 2009
- Korosho to Inspect Generics Containing 5 More APIs
July 13, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…